CAR T-cell therapies targeting specific antigens, such as CD19, have been approved for use in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients who have failed two or more lines of systemic therapy. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.